Send to

Choose Destination
Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x.

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Collaborators (140)

Arechavaleta-Granell M, García-Hernández P, Gonzalez-Galvez G, Gonzalez-Villalpando C, Morales-Flores H, Olvera-Alvarez I, Rios-Rodriguez E, Rodriguez-Pattzi H, Salinas-Gonzalez F, Sauque-Reyna L, Sosa-Camas R, Tamez-Perez H, Violante-Ortiz R, Abbott L, Arakaki R, Bailey T, Blonde L, Bode B, Bressler P, Brusco O, Chisholm O, Rothman J, Corbett B, Cullen E, Downey H, Duckor S, Farmer H, Farrell J, Feinglos M, Fusco F, Garber A, Goldstein B, Gollapudi G, Graf R, Greco S, Hartman I, Hassman D, Mudaliar S, Hodge R, Hoffman B, Hollander P, Kaplan R, Kapoor A, Kawley F, Klein E, Landgarten S, Carroll M, Leslie H, Licata A, Linden D, Lipetz R, McGill J, Clarke D, Mezitis N, Norris L, Mulmed L, Myers L, Ollins R, Palte S, Pearlstein R, Peterson G, Phillips L, Popeil L, Powers C, Race J, Rivera-Colon L, Rosenstock J, Sharma S, Schumacher D, Schwartz S, Shelmet J, Shepherd M, Silver B, Snell P, Snyder B, Sugimoto D, Sussman A, Tamayo R, Tisovec R, Cheatham W, Wahl T, Warren M, Weinrib S, Weinstein R, Weinstock R, Weiss D, Williams R, Witkin D, Cox M, Zisser H, East H, Barrera J, Gilman R, Robinson M, Pullman J, Ajani D, Reichman A, Thigpen D, Zieve F, Fishman N, Mather K, Abelseth J, Corder C, Griffing G, Huffman D, Garcia-Soria-Davis M, Granados Reyes S, Gallen J, Furlong K, Uwaifo G, Aroda V, Wynne A, Gupta A, Oberoi M, Brunner J, Christensen R, Lucas K, Baron M, Picciano M, Prasad S, Reed L, Silver G, Dunn L, Sperling M, Sullivan J, Levinson L, Beecher A, Marple R, Rasor D, Idowu O, Khan J, Oyer D, Topkis R, Spees R, Peniston J, Ryckman G, Philis-Tsimikas A, Gaona R, Askari N, Choi L.

Author information

Department of Medicine and the Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA.



Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years.


Participants were randomized to receive once-daily liraglutide 1.2 mg, liraglutide 1.8 mg or glimepiride 8 mg. Participants completing the 1-year randomized, double-blind, double-dummy period could continue open-label treatment for an additional year. Safety data were evaluated for the full population exposed to treatment, and efficacy data were evaluated for the full intention-to-treat (ITT) and 2-year completer populations. Outcome measures included change in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight and frequency of nausea and hypoglycaemia.


For patients completing 2 years of therapy, HbA1c reductions were -0.6% with glimepiride versus -0.9% with liraglutide 1.2 mg (difference: -0.37, 95% CI: -0.71 to -0.02; p = 0.0376) and -1.1% with liraglutide 1.8 mg (difference: -0.55, 95% CI: -0.88 to -0.21; p = 0.0016). In the ITT population, HbA1c reductions were -0.3% with glimepiride versus -0.6% with liraglutide 1.2 mg (difference: -0.31, 95% CI: -0.54 to -0.08; p = 0.0076) and -0.9% with liraglutide 1.8 mg (difference: -0.60, 95% CI: -0.83 to -0.38; p < 0.0001). For both ITT and completer populations, liraglutide was more effective in reducing HbA1c, FPG and weight. Over 2 years, rates of minor hypoglycaemia [self-treated plasma glucose <3.1 mmol/l (<56 mg/dl)] were significantly lower with liraglutide 1.2 mg and 1.8 mg compared with glimepiride (p < 0.0001).


Liraglutide monotherapy for 2 years provides significant and sustained improvements in glycaemic control and body weight compared with glimepiride monotherapy, at a lower risk of hypoglycaemia.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center